Suzhou Ribo Life Science (HKG:6938) said its stock has been added as a constituent of the Hang Seng Composite Index, and that its shares have been included in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, effective Monday.
The biotech firm said its inclusion in the index and cross-border trading links would improve its share liquidity, broaden its investor base and enhance its visibility in the capital markets, according to a Monday disclosure.
The Stock Connect programs are a collaboration between the Hong Kong, Shanghai and Shenzhen stock exchanges, enabling international and mainland Chinese investors to trade securities in each other's markets.